Toripalimab plus chemotherapy as first-line treatment for advanced oesophageal cancer reaches primary endpoints in Phase III study

The results of an interim analysis of JUPITER-06 show that compared with paclitaxel/cisplatin chemotherapy, toripalimab (anti-PD-1 monoclonal antibody) combined with paclitaxel/cisplatin significantly prolonged progression-free survival and overall survival.

Biospace Inc.